At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Tadalafil +1 moredrug
Likely dose
Tadalafil 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted May 7, 2009·Updated Jun 11, 2019
In Brief
A Phase 2 clinical trial evaluating Tadalafil and Placebo Pill for Head and Neck Squamous Cell Carcinoma. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedMay 2009
Primary CompletionMar 2012
TodayJul 2026
First PostedMay 7, 2009
Enrollment StartMay 8, 2007
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.2 years ago
Interventions
Tadalafildrug
20 mg once daily for 10 - 14 days
Placebo Pillother
Placebo